Table 3 Drug-related adverse events occurring in 10% of patients across all dose levels

From: Phase I study of weekly paclitaxel in combination with pazopanib and lapatinib in advanced solid malignancies

  50 mg m 2 paclitaxel+400 mg pazopanib+1000 mg lapatinib ( n =7) 50 mg m 2 paclitaxel+800 mg pazopanib+1000 mg lapatinib ( n =3) 80 mg m 2 paclitaxel+800 mg pazopanib+1000 mg lapatinib ( n =3) 80 mg m 2 paclitaxel+400 mg pazopanib+1000 mg lapatinib ( n =13) All dose levels ( N =26)
  Maximum CTCAE grade, n (%)  
  1 or 2 3 or 4 1 or 2 3 or 4 1 or 2 3 or 4 1 or 2 3 or 4 Any grade, n (%)
Haematologic
Neutropenia 2 (29) 1 (14) 0 1 (33) 0 2 (67) 1 (8) 6 (46) 13 (50)
Anaemia 0 1 (14) 1 (33) 0 0 1 (33) 4 (31) 0a 7 (27)
Thrombocytopenia 1 (14) 0 1 (33) 0 0 1 (33) 2 (15) 0 5 (19)
Lymphopenia 0 1 (14) 0 1 (33) 0 0 0 2 (15) 4 (15)
Leucopenia 1 (14) 0 0 0 0 0 1 (8) 1 (8) 3 (12)
Nonhematologic
Diarrhoea 4 (57) 0 0 1 (33) 0 0 7 (54) 2 (15) 14 (54)
Fatigue 2 (29) 0 2 (67) 0 2 (67) 1 (33) 6 (46) 0 13 (50)
Nausea 2 (29) 0 2 (67) 0 2 (67) 0 4 (31) 0 10 (38)
Decreased appetite 1 (14) 0 2 (67) 0 2 (67) 0 3 (23) 1 (8) 9 (35)
Alopecia 3 (43) 0 1 (33) 0 0 0 3 (23) 0 7 (27)
Dysgeusia 1 (14) 0 1 (33) 0 1 (33) 0 3 (23) 0 6 (23)
Hypertension 0 0 1 (33) 0 3 (100) 0 1 (8) 1 (8) 6 (23)
Mucosal inflammation 1 (14) 0 1 (33) 0 1 (33) 0 3 (23) 0 6 (23)
Vomiting 2 (29) 0 2 (67) 0 0 0 2 (15) 0 6 (23)
ALT increased 0 1 (14) 1 (33) 1 (33) 0 0 1 (8) 1 (8) 5 (19)
AST increased 0 1 (14) 1 (33) 1 (33) 0 0 1 (8) 1 (8) 5 (19)
Peripheral neuropathy 0 1 (14) 1 (33) 0 2 (67) 0 1 (8) 0 5 (19)
Rash 0 0 1 (33) 0 2 (67) 0 2 (15) 0 5 (19)
Confusional state 1 (14) 0 0 0 0 0 1 (8) 1 (8) 3 (12)
Dizziness 1 (14) 0 1 (33) 0 1 (33) 0 0 0 3 (12)
Dyspepsia 1 (14) 0 0 0 1 (33) 0 1 (8) 0 3 (12)
Epistaxis 2 (29) 0 1 (33) 0 0 0 0 0 3 (12)
Hypoalbuminemia 0 0 1 (33) 0 0 0 2 (15) 0 3 (12)
  1. Abbreviations: ALT=alanine aminotransferase; AST=aspartate aminotransferase; CTCAE=Common Terminology Criteria for Adverse Events.
  2. aThis does not include one patient in the 80 mg m−2 paclitaxel+400 mg pazopanib+1000 mg lapatinib dose level who had grade 3 decreased haemoglobin (7.6 g dl−1) on day 88 that was not captured in either the laboratory or the adverse event database.